Cheng Xu

4.3k total citations · 1 hit paper
106 papers, 1.8k citations indexed

About

Cheng Xu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Cheng Xu has authored 106 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 32 papers in Otorhinolaryngology. Recurrent topics in Cheng Xu's work include Head and Neck Cancer Studies (32 papers), Lung Cancer Treatments and Mutations (17 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Cheng Xu is often cited by papers focused on Head and Neck Cancer Studies (32 papers), Lung Cancer Treatments and Mutations (17 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Cheng Xu collaborates with scholars based in China, United States and Italy. Cheng Xu's co-authors include Jun Ma, Ying Sun, Ling‐Long Tang, Lei Chen, Yu‐Pei Chen, Guan‐Qun Zhou, Ai-Hua Lin, Yan‐Ping Mao, Wen-Fei Li and Chiun Hsu and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Cheng Xu

95 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

2018 416 citations Cheng Xu, Yu‐Pei Chen et al. profile →

Peers

Countries citing papers authored by Cheng Xu

Since Specialization

Citations

This map shows the geographic impact of Cheng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng Xu more than expected).

Fields of papers citing papers by Cheng Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng Xu. The network helps show where Cheng Xu may publish in the future.

Co-authorship network of co-authors of Cheng Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng Xu. A scholar is included among the top collaborators of Cheng Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng Xu. Cheng Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dietary succinate supplementation alleviates DSS-induced colitis via the IL-4Rα/Hif-1α Axis 2025 ·International Immunopharmacology ·(unknown), (unknown), Xiaomei Ouyang, (unknown), Yongdong Huang, Ying Lin, Cheng Xu, (unknown), (unknown), (unknown), (unknown), (unknown), Shih‐Chin Cheng	3
2	Peripheral nerve blocks for hip fracture surgeries: a bibliometric and visual analysis 2025 ·International Journal of Surgery ·Chao Zhang, (unknown), (unknown), Miao Wang, Cheng Xu, Aizhong Wang	1
3	Establishing a knowledge-based planning model for left-sided breast cancer patients receiving hypofractionated postmastectomy and regional nodal irradiation 2025 ·Medical dosimetry ·Shujun Zhang, Mei Chen, (unknown), (unknown), (unknown), Gang Cai, Cheng Xu, Lu Cao, (unknown)	0
4	Systematic dissection of sequence features affecting binding specificity of a pioneer factor reveals binding synergy between FOXA1 and AP-1 2024 ·Molecular Cell ·Cheng Xu, (unknown), Jianyu Yang, (unknown), (unknown), Song Tan, Shaun Mahony, Lu Bai	8
5	Evaluation of an automated clinical decision system with deep learning dose prediction and NTCP model for prostate cancer proton therapy 2024 ·Physics in Medicine and Biology ·(unknown), Bo Pang, (unknown), Cheng Xu, Jiayi Chen, Kunyu Yang, (unknown), Zhiyong Yang	2
6	The emerging role of PANoptosis in viral infections disease 2024 ·Cellular Signalling ·Cheng Xu, Tao Zeng, Yingshu Xu, Yongai Xiong	5
7	Physical activity lowers all-cause and cardio-cerebrovascular mortality in adults with coronary heart disease 2024 ·International Journal of Cardiology ·Lingling Sun, Cheng Xu, Zhi Zhang, Lijiang Tang, Xiaowei Liu	1
8	Radiotherapy Target Volume Delineation Based on Post-Induction Chemotherapy Gross Tumor Volume vs. Pre-Induction Volume for Locoregionally Advanced Nasopharyngeal Carcinoma: An Open-label, Non-Inferiority, Multicenter, Randomized Phase III Trial 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Jinan Ma, Ling‐Long Tang, Liangyi Chen, Guangqing Xu, Chenglong Huang, Rui Guo, (unknown), Yan‐Ping Mao, Guan‐Qun Zhou, Lin Lü, Ying Zhang, Li Lin, Lizhi Liu, (unknown), (unknown), Cheng Xu, Fang‐Yun Xie, Nan Zhang, Ying Sun	2
9	Chemotherapy‐Induced Senescence Reprogramming Promotes Nasopharyngeal Carcinoma Metastasis by circRNA‐Mediated PKR Activation 2023 ·Advanced Science ·Qian Li, (unknown), Cheng Xu, Ye‐Lin Liang, Yin Zhao, Qing‐Mei He, Junyan Li, Kailin Chen, Han Qiao, Na Liu, Jun Ma, Lei Chen, Ying‐Qin Li	35
10	Prognostic implication and immunotherapy response prediction of a ubiquitination-related gene signature in breast cancer 2023 ·Frontiers in Genetics ·Yangyang Guo, Qiaoqiao Chen, (unknown), Cheng Xu, (unknown), Ying Dai, (unknown), (unknown), (unknown)	3
11	A single center retrospective study assessing the prognostic significance of pre-treatment neutrophil/lymphocyte ratio in locally advanced nasopharyngeal carcinoma 2023 ·Translational Cancer Research ·Fei Xu, (unknown), Xin Hua, Cheng Xu, Jiayi Chen, Weiguo Cao, Gao Yun-sheng	3
12	Evolving landscape and academic attitudes toward the controversies of global immuno‐oncology trials 2021 ·International Journal of Cancer ·Cheng Xu, Shu Zhang, Yuan Zhang, Siqi Tang, Xueliang Fang, (unknown), Liang Peng, (unknown), Yan‐Ping Mao, Ling‐Long Tang, Qing Liu, Aihua Lin, Ying Sun, Jun Ma	3
13	RNA-binding protein MEX3A controls G1/S transition via regulating the RB/E2F pathway in clear cell renal cell carcinoma 2021 ·Molecular Therapy — Nucleic Acids ·Yuntan Qiu, Meng Meng, (unknown), Jingyuan Zhang, Cheng Xu, Yongxin Huang, (unknown), Yun Li, (unknown), Yongsheng Huang, Li Peng, Kaishun Hu, Yin Zhang, Jian‐You Liao, Jiehua He, Xiaochun Wang, Daning Lu, Lehang Lin, Xingang Bi, Dong Yin	7
14	Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial 2021 ·Radiotherapy and Oncology ·Siqi Tang, Lei Chen, Wen‐Fei Li, Anthony T.�C. Chan, Shao Hui Huang, Melvin L.K. Chua, Brian O’Sullivan, Anne W.M. Lee, Nancy Y. Lee, Yuan Zhang, Yu‐Pei Chen, Cheng Xu, Ying Sun, Ling‐Long Tang, Jun Ma	17
15	Low expression of BTN3A3 indicates poor prognosis and promotes cell proliferation, migration and invasion in non-small cell lung cancer 2021 ·Annals of Translational Medicine ·Cheng Xu, Tianyu Ma, Ling Yi, Chongyu Su, (unknown), Tao Wen, Bing Wang, Yuxuan Wang, Hongtao Zhang, Zhidong Liu	8
16	Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis 2020 ·Oral Oncology ·(unknown), Cheng Xu, (unknown), Ling‐Long Tang, Wen-Fei Li, Lei Chen, Yan‐Ping Mao, Rui Guo, Qing Liu, Ying Sun, Jun Ma	14
17	AR-induced long non-coding RNA LINC01503 facilitates proliferation and metastasis via the SFPQ-FOSL1 axis in nasopharyngeal carcinoma 2020 ·Oncogene ·Shiwei He, Cheng Xu, Ying-Qing Li, Ying‐Qin Li, Yin Zhao, Panpan Zhang, Yuan Lei, Ye‐Lin Liang, Junyan Li, Qian Li, Yang Chen, Sheng‐Yan Huang, Jun Ma, Na Liu	29
18	Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort 2018 ·Oral Oncology ·Liang Peng, Cheng Xu, Yu‐Pei Chen, Rui Guo, Yan‐Ping Mao, Ying Sun, Jun Ma, Ling‐Long Tang	15
19	Association Between 12 Polymorphisms of VEGF/Hypoxia/Angiogenesis Pathway Genes and Risk of Urogenital Carcinomas: A Meta-Analysis Based on Case-Control Studies 2018 ·Frontiers in Physiology ·Jinbo Chen, Meng Zhang, Yu Cui, Peihua Liu, Weiqi Yan, Chao Li, Cheng Xu, Wenbiao Ren, Qiaqia Li, Longfei Liu, Minfeng Chen, Hequn Chen, Xiongbing Zu	5
20	Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma 2017 ·Journal of the National Comprehensive Cancer Network ·Yu‐Pei Chen, Yaqin Wang, Wen-Fei Li, Lei Chen, Cheng Xu, Tai-Xiang Lu, Ai-Hua Lin, Ji‐Jin Yao, (unknown), Ying Sun, Yan‐Ping Mao, Jun Ma	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact